| Price | 0.65 |
| Price Change Today | -$0.01 (-1.52%) |
| P&P rating | ![]() |
| Zacks Rank | 3 - HOLD |
| Open Price | $0.68 |
| Previous Close | $0.66 |
| Daily Range | $0.63 - $0.68 |
| 52-Week Range | $0.36 - $1.84 |
| Volume | 338,877 |
| CYCLACEL is a biopharmaceutical company dedicated to the discovery, development and commercialization of novel, mechanism-targeted drugs to treat human cancers and other serious disorders. Three orally-available Cyclacel drugs are in clinical development. Sapacitabine, a cell cycle modulating nucleoside analog, is in Phase 2 studies for the treatment of acute myeloid leukemia in the elderly, myelodysplastic syndromes and cutaneous T-cell lymphoma. Seliciclib (CYC202 or R-roscovitine), a CDK inhibitor, is in Phase 2 for the treatment of lung cancer and nasopharyngeal cancer. | |




Comments: 0 | Comment
Comments: 0 | Comment